<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Data regarding flow cytometry (FC) in nonacute myeloid disorders is confounded by variable gating strategies and controls limited to <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow (BM) samples </plain></SENT>
<SENT sid="1" pm="."><plain>Blasts in diagnostic BM samples of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs), myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPNs), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMMLs</z:e>) were compared with 20 nonneoplastic cytopenias/cytoses (CCs) and negative staging BM samples using 4-color FC </plain></SENT>
<SENT sid="2" pm="."><plain>Blasts in 10 of 20 CCs showed immunophenotypic differences vs control samples </plain></SENT>
<SENT sid="3" pm="."><plain>Immunophenotypic alterations were identified in 18 of 21 MDSs, 11 of 14 MPNs, and 7 of 7 CMMLs vs control samples and 13 (62%) of 21 MDSs, 7 (50%) of 14 MPNs, and 3 (43%) of 7 CMMLs vs CCs </plain></SENT>
<SENT sid="4" pm="."><plain>Neoplastic-specific blast immunophenotypic changes included expression of CD7, CD11b, CD15, CD36, and CD56; CD34 overexpression; HLA-DR variability; lack of CD13 and CD33; underexpression of CD13, CD33, CD45, and HLA-DR; and partial loss of CD13, CD33, CD38, and CD117 </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases, blasts were CD34+ </plain></SENT>
<SENT sid="6" pm="."><plain>Several blast immunophenotypic alterations are shared in neoplastic and nonneoplastic BM samples </plain></SENT>
<SENT sid="7" pm="."><plain>Approximately 40% to 60% of neoplastic BM samples exhibited aberrancies not seen in reactive BM samples </plain></SENT>
</text></document>